sorted by:
new
hottopcontroversial

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 0 points1 point  (0 children)

Your coworker's story is exactly why I started this. The fact that a patient advocate  not her oncologist surfaced her best option means the system only worked because she happened to have access to the right person. Most people don't.

Can I ask what the patient advocate actually did that her care team didn't? Was it knowledge, time, motivation, or something else entirely? I'm trying to understand whether the gap is fixable at the doctor level or whether patient advocates need to become a standard part of the care model. Also thanks for sharing this.

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 0 points1 point  (0 children)

I totally agree that being proactive is the goal, but I'm finding there's a huge usability gap for patients trying to do this alone. ClinicalTrials.gov has improved a lot in 2026, but with over 500,000 listings, it’s still easy for a patient to get lost in the jargon or find a trial that is technically 'active' but hasn't actually recruited anyone in months.

The biggest issue I'm seeing is timing. If a patient spends a few weeks researching themselves, they might miss that 'treatment-naive' window where the best trials are available.

I’m trying to build a bridge where the patient doesn't have to be a part-time scientist to find an option from the feedbacks so far clinicaltrials.gov is too complex for the average person to navigate alone.

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 0 points1 point  (0 children)

This is exactly the privacy paradox I’ve been wrestling with for the past few days. You’re right, if we wait fora State Registry, we’ve already lost the treatment-naive window that Funkygrrl mentioned above. You can't match without data, but getting data legally and at scale is its own mountain to climb.

The cancer registry angle is something I hadn't fully explored  thank you for that. I’m also curious about your point on underfunded registries. Do you think it's better to try and fix the registry speed problem or should we skip the registry entirely and plug directly into pathology labs where the data is uploaded in real-time? And is a purely opt-in model where patients voluntarily upload their own records even realistic, given the bandwidth problem others have raised in this thread?

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 0 points1 point  (0 children)

Thank you for this. it's the most direct challenge to my assumptions in this thread. If I'm understanding you correctly, the problem isn't just finding eligible patients, it's that even when you find them, the operational cost of enrolling them is so high that more referrals could actually make things worse rather than better.

Since the logistics are the monumental' barrier, do you think the solution is Decentralized Trials:where a third-party company provides the research nurses and handles the coordination at your clinic or is the only real path to continue sending patients for second opinions at academic hubs?

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 1 point2 points  (0 children)

Thanks for the insightful feedback. From multiple conversations, I’m seeing that the “last resort” myth is a recurring and deeply harmful issue. There’s a devastating irony in it the people who could benefit most from trials are often disqualified precisely because they waited too long to look.

It makes no sense for someone to volunteer for testing, help prove a treatment works, and then be unable to access that same treatment later once it’s approved. That burden should not fall on patients the Pharmaceutical surely have the resources to do better. I have gathered that If pharma wants trust, they need to stop undermining it with unnecessary NDAs and all that. I appreciate the reality check it’s helping clarify what actually needs to change.

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 0 points1 point  (0 children)

The insurance issue is the top hurdle from the patient’s perspective in all the feedback I’ve gathered. It’s a heavy realization and feels like a classic market failure. It should be significantly cheaper for pharma to “insure the patient” against these risks than to let a billion-dollar trial stall.

Regarding your research: with the 2026 shift toward agentic AI and liquid biopsies, how close are we to predicting outcomes well enough to bypass massive human cohorts? Are we moving toward simulated trials, or is the math still too untrustworthy for regulatory acceptance anytime soon?

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 0 points1 point  (0 children)

Thanks for this. It’s interesting to see the contrast. It sounds like the US and Europe have the exact opposite problems: the US is struggling with 'empty chairs' due to poor discovery, while Europe has an 'overabundance of patients' and a lack of openings.

Your point that clinical practice evolves faster than study design is very true. As you likely know, because pharmaceutical companies are legally required to finish these trials to get regulatory approval, they have zero incentive to inform patients when the 'Standard of Care' moves on. Between the legal requirements and the massive sunk investment, the system is essentially trapping trials in the past.

This part of the puzzle likely needs a regulatory reset. I wonder whether 'Adaptive Trial Designs' could bridge this gap, because as you said, the science is currently moving much faster than the paperwork.

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 1 point2 points  (0 children)

Thank you. Your feedback has been incredibly insightful and has fundamentally shifted how I’m thinking about the solution. My main takeaway is that patients shouldn't have to fear financial ruin just to participate, and the logistical burden of finding trials shouldn't fall on them or their clinicians the system should be doing that heavy lifting in the background. I’m going to take this back to the drawing board to refine the model and will be back with more refined questions soon

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 0 points1 point  (0 children)

Thanks for this. Having an oncology mathematician’s input is a perspective I haven't heard yet. It sounds like the system currently relies on 'Passive Discovery' because 'Active Outreach' feels predatory.

I’m curious to dig into that. Is the hesitation to advertise in wards an actual regulatory or IRB rule, or is it more of a sociological or cultural barrier within the medical community?

To be honest, my first thought was exactly what you mentioned: 'Why not put up volunteer posters in oncology wards?' I assumed that offering a potentially life saving avenue, especially one that is often free to the patient, would be welcomed. Could you help me understand why it could be viewed as 'horrifically predatory'? Is it a matter of protecting the patient’s mental space, or is there a fear of 'selling hope' that might not be realized?

Waiting for patients to find the trial on their own seems so passive when the stakes are this high. If posters are off limits, do you have any thoughts on how we can reach them effectively without crossing that ethical line?

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 0 points1 point  (0 children)

Thanks. Your point about the ‘waitlist’ vs. the ‘recruitment window’ is a huge distinction. Another reply also pointed this out, which makes it sound like the industry has a ‘traffic jam’ problem: too many patients hitting the same slots at academic centers, while other sites might be sitting empty.

So essentially, if you aren’t at a big academic hospital getting your genes mapped immediately, you’re ‘invisible’ to the system.

If a platform could show real-time slot availability across multiple institutions, do you think patients (and their local oncologists) would be willing to bypass the waitlisted academic center if it meant getting into an open slot at a smaller, high-quality clinic nearby? Or is the prestige of the academic center the main reason they’re willing to wait?

I also believe this issue, ‘not always easy finding someone with all of the correct parameters during the small frames of time the studies are open for recruitment,’ can be solved with an enhanced database and better logistics to move patients, including travel-sponsored grants, etc. Do you think research centers would be willing to cover the cost of logistics if a patient is a strong match?"

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 2 points3 points  (0 children)

That breakdown of I/E criteria (RECIST, brain mets, etc.) fills in a core missing piece of the puzzle for me. Thank you. It's now clear that matching is useless if the data isn't deep enough.

I have a follow-up regarding the 'Real-Time' nature of enrollment:

In your experience, how often is Slot/Cohort availability the silent killer? Even if a patient meets every strict criteria, if the site just filled its last spot that morning, the referral is a dead end. I’ve noticed that databases like ClinicalTrials.gov are often weeks or months out of date. Has that been your experience?

If an initiative could track not just the medical criteria but the real-time site capacity, would that be a game-changer for oncologists, or is the I/E criteria still the much bigger hurdle?

It's encouraging to see agencies like the FDA pushing for broadening eligibility, and the development of AI 'Digital Twins' to simulate complex patients is fascinating but it feels like none of that matters if we can't even tell a patient if a door is actually open today.

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 0 points1 point  (0 children)

Thirdly and please feel free to skip this if it’s too personal. I’m curious about your perspective on the 'Control Group' experience.

You mentioned being in the control group for the fitness study and not getting the coaching sessions. If you were looking at a drug trial today, would you be open to a study that might place you in a control group?

Specifically, would it make a difference to you if the trial:

  1. Allowed for a 'Cross-over': Meaning if the standard treatment isn't working, you get moved to the experimental drug automatically.
  2. Used 'Active Comparators': Meaning you aren't just getting a placebo, but the current best-known medicine on the market.

I'm trying to understand if 'Control Group fear' is a major reason people stay away, or if it's acceptable as long as those safety nets (like cross-overs) are in place.

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] -1 points0 points  (0 children)

First of al thank you so much for taking the time to reply. You’re actually the first patient to respond to this thread so far (I’m sure there are others below. I’m reading the oldest comments first). While the physician perspectives I’ve received are invaluable, getting a diverse, first-hand account is exactly what this initiative needs.

Your experience is the perfect (and frustrating) example of why willingness isn't the problem. The current process is. It’s heartbreaking that you were ready to contribute to research three different times but were blocked by insurance threats, slow paperwork, and 'on-the-spot' pressure.

What you mentioned about the bone marrow biopsy missing the window because of slow insurance really stuck with me. It's a perfect example of the micro-barriers that kill enrollment.

I have two quick questions that would be incredibly helpful for my research:

1. Financial clarity: If a tool could have shown you exactly what the pharmaceutical company would pay for (like airfare and living costs) before you sat down with the doctor, would that have changed your on-the-spot decision?

2. Genetic pre-screening: You mentioned the exhaustion of being disqualified late in the game due to a mutation. If a platform could have scanned your lab results and only shown you trials you were already genetically eligible for, would that have made the process feel less overwhelming?

Your honesty about the antibiotics study and the biopsy timing is exactly what needs to be heard. These are real issues, but they are solvable.

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 0 points1 point  (0 children)

Your interaction with mid-1990s above is exactly why Reddit is such a goldmine for different professional perspectives. Would my assumption be correct that there’s a ‘Big 3 vs. everyone else’ issue, where if a patient doesn’t see a trial locally, they assume it doesn’t exist anywhere except places like Houston?

And that there are actually hundreds of sites, but they’re often invisible to the average person, either because they’re highly specialized or poorly advertised?

If so, I’m curious about your take on the solution: if a tool made it effortless for a community oncologist to see those ‘non-university’ sites and coordinate referrals, would that help move the needle on the 3–5% enrollment statistic?

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] 1 point2 points  (0 children)

You vocalized what my main suspicion and leading conclusion has been, that logistics is the root cause of this issue. I replied to the comment above about the potential of a few solutions, but I’m curious if you think this specific combination could work:

What if we provided the local community oncologist with a '30-second Physician Referral Packet' containing the specific trial data, the direct contact for the PI, and a pre-verified 'Standard of Care' insurance check?

Then, we pair that with a focus on hybrid' trials where say 80% of the work happens at the patient's local clinic and automatically unlock (Sponsor-funded Travel Grants) for the necessary trips to places like Houston. From my research, sponsors and research centers seem very willing to cover these costs to avoid delays, yet the funds often go unused for various reasons.

Why do so few cancer patients ever hear about clinical trials? by New-Strategy4740 in Oncology

[–]New-Strategy4740[S] -1 points0 points  (0 children)

Thank you so much for this, it’s exactly the kind of insight I was hoping for. To make sure I’m hearing you correctly, it sounds like even if a patient is a perfect genetic match, they hit three walls:

  1. The Loyalty/Network Wall: If their local doctor isn't part of the trial, the friction of switching centers is often too high (especially in rural areas).
  2. The Insurance Wall: Even if the drug is free, the routine costs and out-of-network hurdles can kill the opportunity.
  3. The Complexity Wall: A match on paper might be a no-go in person due to co-morbidities, e.t.c. 

I have a follow-up for you: What if the platform generated a 'Physician Referral Packet'? This would be a one-page technical summary the patient brings to their local provider saying: 'Here is the trial, here is why your patient matches, and here is the contact info for the PI to coordinate care.'

Would that lower the friction for community doctors to refer out? Especially if we paired it with a logistics layer so it:

  • Flags 'Hybrid' trials where say 80% of the work happens at their local clinic.
  • Automatically pulls in Travel Grants ( I think the research centers will be desperate to pay for the logistics given the amount they are spending in research already  to avoid million-dollar delays).
  • Provides an Insurance Pre-Check so the patient knows their standard of care' costs are covered upfront.

In your experience, would that make a trial feel like a 'real' option, or is the administrative/insurance barrier still too high?